In clinical practices, the presence of tumor-infiltrating lymphocytes within primary cancer lesions, including CD8+ cytotoxic T lymphocytes and peritumor-infiltrating NK cells, has been known to be associated with neoadjuvant chemotherapeutic efficacy in terms of the post-treatment reduction in tumor size and with prolonged disease-free survival of breast cancer patients [7,8,9,10]. Here, CD8A is linked to neoplasm.